Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of andrographolide and dexamethasone to preparation of compound medicines for resisting acute lymphoblastic leukemia

A technology of acute lymphocytes and andrographolide, applied in the field of medicine, can solve the problems of poor curative effect, easy to cause drug resistance, poor prognosis, etc., achieve difficult drug resistance, reduce toxic side effects and drug resistance, and change distribution Effect

Active Publication Date: 2020-09-15
GUILIN MEDICAL UNIVERSITY
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing drugs for the treatment of acute lymphoblastic leukemia with dexamethasone as the mainstream are not only easy to cause adverse reactions such as hypertension and osteoporosis due to long-term and high-dose use, but also have poor curative effect and are more likely to cause drug resistance, so that poor prognosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of andrographolide and dexamethasone to preparation of compound medicines for resisting acute lymphoblastic leukemia
  • Application of combination of andrographolide and dexamethasone to preparation of compound medicines for resisting acute lymphoblastic leukemia
  • Application of combination of andrographolide and dexamethasone to preparation of compound medicines for resisting acute lymphoblastic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1: The combination of andrographolide and dexamethasone has an inhibitory effect on the proliferation of human acute lymphoblastic leukemia cells

[0056] Take human acute lymphoblastic leukemia cells (hereinafter referred to as CEM / C1 cells) in the logarithmic phase of growth, and press 1×10 5 Cell / mL density, use 1640 complete medium to make a single cell suspension. Among them, 1640 complete medium is prepared according to the following volume ratio: 1640 medium (Gibco, 500ml): fetal bovine serum (Uruguay Lonsera, 500ml): penicillin and streptomycin mixed solution (Hyclone company, 100ml)=89:10 :1.

[0057] The experimental settings were drug-dosing group, blank control group and solvent control group. details as follows:

[0058] Take the above single cell suspension, inoculate 100 μl / well in a 96-well plate, set up 3 duplicate wells for each experimental group, and add drugs according to the following groups after 24 hours:

[0059] 1. Dosing group: dif...

Embodiment 2

[0080] Embodiment 2: Lysosome red fluorescent probe (abbreviated as Lyso-Tracker Red) detects the test of lysosome pH value

[0081] Four groups were set up in the experiment, as follows:

[0082] 1. Blank control group (Control).

[0083] 2. 5μM andrographolide alone group.

[0084] 3. 50μM dexamethasone alone group.

[0085] 4. The combination group of 5 μM andrographolide plus 50 μM dexamethasone.

[0086] Take human acute lymphoblastic leukemia cells in the logarithmic phase of growth, transfer them to a 15mL centrifuge tube, centrifuge at 1000rpm / min for 5min, add 2ml of 1640 complete medium to resuspend the cells, and then use 1640 complete medium to adjust the cell density to 5× 10 4 cell / mL, seeded in a 6-well plate, 2 mL of cell suspension per well, and added corresponding concentrations of drugs to intervene the cells. After placing the 6-well plate in a cell culture incubator for 24 hours, they were transferred to 15mL centrifuge tubes and centrifuged at 1000rp...

Embodiment 3

[0101] Example 3: Real-time quantitative PCR detection of the expression of glucocorticoid receptor GR and autophagy gene Beclin-1 at the RNA level

[0102] 1. Experimental method

[0103] 1.1 Extraction and concentration determination of human acute lymphoblastic leukemia cell RNA

[0104] The experiments were divided into four groups, as follows:

[0105] (1) Blank control group (Control).

[0106] (2) 5μM andrographolide alone group.

[0107] (3) 50μM dexamethasone single use group.

[0108] (4) 5 μM andrographolide plus 50 μM dexamethasone combined group.

[0109] Take human acute lymphoblastic leukemia cells in the logarithmic phase of growth, transfer them to a 15mL centrifuge tube, centrifuge at 1000rpm / min for 5min, add 2ml 1640 complete medium to resuspend the cells, and then use 1640 complete medium to adjust the cell density to 5×10 4 cell / mL, seeded in a 6-well plate, 2 mL of cell suspension per well, and added corresponding concentrations of drugs to interven...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of combination of andrographolide and dexamethasone to preparation of compound medicines for resisting acute lymphoblastic leukemia, and belongs to the technicalfield of medicines. The combination of the andrographolide and the dexamethasone can be used for preparing the compound medicines for resisting acute lymphoblastic leukemia. An autophagy process is restrained, so that the expression of effect target of dexamethasone -glucocorticoid receptors is increased, and sensibility of organisms to the dexamethasone is improved. A new application field of the andrographolide and the dexamethasone is opened up, new compound medicines for resisting acute lymphoblastic leukemia are also opened up, and the combination has positive pharmaceutical value and broad social significance. The invention further discloses the compound medicines for resisting acute lymphoblastic leukemia. The compound medicines for resisting acute lymphoblastic leukemia can effectively treat the acute lymphoblastic leukemia, and are obvious in treatment effect, and small in toxic and side effect, and reverse tolerance is not liable to generate.

Description

technical field [0001] The invention relates to the application of combined use of andrographolide and dexamethasone in the preparation of compound anti-acute lymphocytic leukemia medicine, which belongs to the technical field of medicine. Background technique [0002] Acute Lymphoblastic Leukemia (ALL) is a clonal disease characterized by B or T lineage. ALL is a high incidence of hematological malignancies and one of the most common malignancies in the world. The diagnosis of acute lymphoblastic leukemia is characterized by the presence of large numbers of lymphoblastoid cells, or lymphocytes, in the bone marrow and peripheral blood, which can spread to the lymph nodes, spleen, liver, central nervous system, and other organs. [0003] Glucocorticoids (glucocorticoids, GCs) drugs, such as dexamethasone (Dexamethasone, dexamethasone) are used as one of the first choice drugs for chemotherapy ALL. Dexamethasone is the basic chemotherapy drug for clinical treatment of acute ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/573A61P35/02
CPCA61K31/365A61K31/573A61P35/02A61K2300/00
Inventor 周越菡徐勤邓健志张建楠李晓文孙建翔
Owner GUILIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com